Logo image of ADAG

ADAGENE INC-ADR (ADAG) Stock Fundamental Analysis

NASDAQ:ADAG - Nasdaq - US0053291078 - ADR - Currency: USD

1.53  -0.05 (-3.16%)

Fundamental Rating

2

Overall ADAG gets a fundamental rating of 2 out of 10. We evaluated ADAG against 568 industry peers in the Biotechnology industry. Both the profitability and financial health of ADAG have multiple concerns. ADAG has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ADAG has reported negative net income.
In the past year ADAG has reported a negative cash flow from operations.
In the past 5 years ADAG always reported negative net income.
ADAG had a negative operating cash flow in each of the past 5 years.
ADAG Yearly Net Income VS EBIT VS OCF VS FCFADAG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

ADAG's Return On Assets of -37.44% is in line compared to the rest of the industry. ADAG outperforms 59.51% of its industry peers.
The Return On Equity of ADAG (-66.16%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -37.44%
ROE -66.16%
ROIC N/A
ROA(3y)-35.43%
ROA(5y)-39.1%
ROE(3y)-63.08%
ROE(5y)-60.3%
ROIC(3y)N/A
ROIC(5y)N/A
ADAG Yearly ROA, ROE, ROICADAG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ADAG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADAG Yearly Profit, Operating, Gross MarginsADAG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K

More info and screens

3

2. Health

2.1 Basic Checks

ADAG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ADAG has been increased compared to 1 year ago.
The number of shares outstanding for ADAG has been increased compared to 5 years ago.
ADAG has a worse debt/assets ratio than last year.
ADAG Yearly Shares OutstandingADAG Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ADAG Yearly Total Debt VS Total AssetsADAG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -4.43, we must say that ADAG is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -4.43, ADAG perfoms like the industry average, outperforming 43.13% of the companies in the same industry.
ADAG has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of ADAG (0.10) is worse than 65.85% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z -4.43
ROIC/WACCN/A
WACC8.65%
ADAG Yearly LT Debt VS Equity VS FCFADAG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 2.30 indicates that ADAG has no problem at all paying its short term obligations.
ADAG has a worse Current ratio (2.30) than 72.54% of its industry peers.
ADAG has a Quick Ratio of 2.30. This indicates that ADAG is financially healthy and has no problem in meeting its short term obligations.
ADAG has a worse Quick ratio (2.30) than 70.95% of its industry peers.
Industry RankSector Rank
Current Ratio 2.3
Quick Ratio 2.3
ADAG Yearly Current Assets VS Current LiabilitesADAG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for ADAG have decreased strongly by -71.88% in the last year.
The Revenue for ADAG has decreased by -99.43% in the past year. This is quite bad
ADAG shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -26.47% yearly.
EPS 1Y (TTM)-71.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.81%
Revenue 1Y (TTM)-99.43%
Revenue growth 3Y-78.36%
Revenue growth 5Y-26.47%
Sales Q2Q%-87.35%

3.2 Future

Based on estimates for the next years, ADAG will show a small growth in Earnings Per Share. The EPS will grow by 4.90% on average per year.
Based on estimates for the next years, ADAG will show a very strong growth in Revenue. The Revenue will grow by 30.73% on average per year.
EPS Next Y-16.1%
EPS Next 2Y-10.76%
EPS Next 3Y-14.03%
EPS Next 5Y4.9%
Revenue Next Year-27.93%
Revenue Next 2Y6.54%
Revenue Next 3Y3.86%
Revenue Next 5Y30.73%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ADAG Yearly Revenue VS EstimatesADAG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
ADAG Yearly EPS VS EstimatesADAG Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ADAG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADAG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADAG Price Earnings VS Forward Price EarningsADAG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADAG Per share dataADAG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

ADAG's earnings are expected to decrease with -14.03% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.76%
EPS Next 3Y-14.03%

More info and screens

0

5. Dividend

5.1 Amount

ADAG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADAGENE INC-ADR

NASDAQ:ADAG (4/17/2025, 8:00:48 PM)

1.53

-0.05 (-3.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-24 2025-03-24/amc
Earnings (Next)07-23 2025-07-23
Inst Owners23.94%
Inst Owner Change0%
Ins Owners3.25%
Ins Owner ChangeN/A
Market Cap72.08M
Analysts77.78
Price Target10.31 (573.86%)
Short Float %0.06%
Short Ratio0.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)11.8%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-3.15%
EPS NY rev (3m)20.49%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-29.82%
Revenue NY rev (3m)-29.82%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 698.43
P/FCF N/A
P/OCF N/A
P/B 1.43
P/tB 1.43
EV/EBITDA N/A
EPS(TTM)-0.72
EYN/A
EPS(NY)-0.78
Fwd EYN/A
FCF(TTM)-0.63
FCFYN/A
OCF(TTM)-0.63
OCFYN/A
SpS0
BVpS1.07
TBVpS1.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.44%
ROE -66.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.43%
ROA(5y)-39.1%
ROE(3y)-63.08%
ROE(5y)-60.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.65%
Cap/Sales 32.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.3
Quick Ratio 2.3
Altman-Z -4.43
F-Score2
WACC8.65%
ROIC/WACCN/A
Cap/Depr(3y)24.44%
Cap/Depr(5y)80.95%
Cap/Sales(3y)13.48%
Cap/Sales(5y)39.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-71.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.81%
EPS Next Y-16.1%
EPS Next 2Y-10.76%
EPS Next 3Y-14.03%
EPS Next 5Y4.9%
Revenue 1Y (TTM)-99.43%
Revenue growth 3Y-78.36%
Revenue growth 5Y-26.47%
Sales Q2Q%-87.35%
Revenue Next Year-27.93%
Revenue Next 2Y6.54%
Revenue Next 3Y3.86%
Revenue Next 5Y30.73%
EBIT growth 1Y-51.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-37.37%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-4.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4.38%
OCF growth 3YN/A
OCF growth 5YN/A